The Effect of Anacetrapib on Vascular Function and Arterial Stiffness
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
There are currently no studies evaluating the effect of anacetrapib on blood vessel function
and stiffness of the arteries. The REVEAL-Vasc trial will assess whether anacetrapib, in
addition to atorvastatin (LDL-C lowering drug) treatment, results in greater
endothelial-dependent vascular function and aortic stiffness in patients with established
cardiovascular disease, compared to adding placebo.
Participants will be asked to provide a blood sample and pulse Wave Velocity/Pulse Wave
Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and
stiffness of the arteries. REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55:
REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification): A
large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among
people with established vascular disease (NCT01252953) which is coordinated by OXFORD CTSU.
No treatment will be received on this sub-study, therefore only participants who have been
enrolled in HPS3/TIMI55 REVEAL in which participants received anacetrapib with atorvastatin
or placebo will be considered for this trial.
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborator:
British Heart Foundation Cambridge Centre of Excellence